Neoadjuvant chemotherapy (NAC) has become the main treatment option for breast cancer. Its adverse drug reactions (ADRs) make NAC painful both physiologically and psychologically. The factor pathological complete remission (pCR) describes how well a series of six or more chemotherapeutic treatments works on a patient. This study investigated the possibility of predicting pCR using only the nodal sizes of the first three treatments. A best feature combination for each breast cancer subtype was screened from the real nodal sizes of the first three treatments and the nodal sizes' of the next three treatments predicted from those of the first three ones. The prediction was evaluated by the metrics Avc = (sensitivity + specificity)/2. A triple-negative breast cancer (TN) patient may have an estimation of pCR Avc = 0.8696 after taking just three treatments. At least Avc = 0.7594 was achieved for all the four breast cancer subtypes investigated in this study.
I. INTRODUCTION
Breast cancer is one of the most frequently occurred cancer type for females [1] , [2] and exceeds the combined incidences of the next three top-ranked female cancer types in the United States, i.e., lung & bronchus, colon & rectum, and uterine corpus [3] . It is also the top-ranked cancer type for females in China [4] - [6] and its incidence rate keeps increasing since 2000 [7] . Despite the invention and deployment of many diagnosis and treatment techniques [8] , [9] , breast cancer is among the top two ranked cancer types for The associate editor coordinating the review of this manuscript and approving it for publication was Ran Su.
annual mortalities in both countries [3] , [7] . Tumor size is one of the main factors positively correlated with the longterm mortality [10] - [13] and it is recommended to use various screening technologies to detect breast cancer smaller than 2 cm [14] , [15] .
Subtypes of breast cancer varied significantly in both pathological phenotypes and have different recommended treatment plans [16] - [18] . Although the incidence rates of all the breast cancer subtypes increase with the age, they tend to have different tumor sizes. The subtype luminal A tends to have a smaller tumor size than the subtype luminal-HER2. For example, 63% of the luminal A patients have tumor sizes smaller than 2 cm in the British Columbia cohort, VOLUME 7, 2019 This work is licensed under a Creative Commons Attribution 4.0 License. For more information, see http://creativecommons.org/licenses/by/4.0/ while 61% of the luminal-HER2 patients have tumors larger than 2 cm [16] . This supports the two previous observations that the subtype luminal A has a longer median survival duration than the subtype luminal-HER2 [19] , [20] , and there is a positive correlation between the tumor size and mortality [10] , [21] - [23] . So a conservative radiation treatment is usually recommended for the subtype luminal A while luminal-HER2 patients need both mastectomy and radiotherapy [16] . Adjuvant chemotherapy is one of the main effective treatment options for breast cancer patients with or without mastectomy [24] . It was reported that a combination of multiple treatment technologies may significantly improve the survival durations of breast cancer patients [25] . While neoadjuvant chemotherapy demonstrated its effectiveness to a wide spectrum of breast cancer subtypes, the drug resistance may rapidly develop and the tumor recurred with a high rate [26] , [27] . Pathologic complete response (pCR) was defined to describe the status of no invasive and no in situ residuals in the breast tissue [28] , [29] , and breast cancer patients with a positive pCR achieved a much better disease-free and overall survival rates [30] . This study investigated the pCR prediction problem using only the data of the first three neoadjuvant chemotherapeutic treatments. Despite its effectiveness, neoadjuvant chemotherapy is notorious for the adverse drug reactions (ADRs), including neutropenia [31] , memory retrieval impairment [32] , muscle and joint pain [33] , and cognitive impairment [34] , [35] , etc. This study firstly trained a classification model for the factor pCR using the clinical data of the first three treatments. Then the data of the next three treatments were predicted by a personalized regression model using those of the first three treatments. The pCR classification model was refined by these predicted data. The proposed algorithm demonstrated satisfying pCR prediction accuracies and achieved the best accuracy for the subtype TN.
II. MATERIALS AND METHODS

A. DATA COLLECTION
This study manually curated the database of the electronic medical records and retrospectively collected the clinical data of 495 breast cancer patients diagnosed and treated with neoadjuvant chemotherapy (NAC) during 2011-2016 at the Department of Breast Surgery in the First Hospital of the Jilin University. 2 male patients were excluded from further analysis, as summarized in Table 1 .
NAC was usually taken to reduce the tumor size before a radical treatment and mostly consisted of sequentially six to eight treatments [36] - [38] . This study hypothesized that the data of the first six NAC treatments were significantly associated with the final pCR status. So this study utilized the clinical data of at least six NAC treatments for each patient. Only the patients with at least six treatments were kept for further analysis. 115 patients with missing clinical data were removed. So among the 378 female patients with at least six chemotherapy treatments, there are 5 sub-types of breast cancer. The sub-type luminal A has only 27 patients, and was excluded from further analysis due to the limited number of samples. The two sub-types of luminal B with HER2 positive and negative have 74 and 154 patients, respectively. They were denoted as ''LBP'' and ''LBN''. The sub-type HER2 (+) has 63 patients and was denoted as HER2. There are 60 triple-negative sub-type patients and this group of patients was denoted as ''TN''. The final cohort has 351 female breast cancer patients from the four sub-types, i.e., LBP, LBN, HER2 and TN. This study was approved by the Institutional Review Board (IRB) of the First Hospital of the Jilin University. This study analyzed the archived medical records and individual patient consent was waived by the IRB of the First Hospital of the Jilin University, including the approval for the waiver request of authorization to collect protected health information.
B. DATA PREPROCESSING
Each patient has the breast cancer nodal sizes for each consecutive chemotherapeutic treatment and the clinical pCR diagnosis. This study assumed that the tumor nodals were rectangles, and a nodal size was measured by the product of the largest diameter and its middle vertical diameter in millimeters. If a patient carried multiple nodals, the sum of the nodal sizes was calculated as the feature for that specific chemotherapeutic treatment of that patient. We observed that some nodal sizes were zero and added a pseudo-one to all the nodal sizes to avoid the division by zeros.
C. PROBLEM SETTING AND PREDICTION ALGORITHMS
The pCR prediction was modelled as a binary classification problem of samples with pCR = 1 or 0 [39] , [40] . Samples were grouped as positive and negative ones, if the pCRs values were 1 and 0, respectively. That is to say, the value pCR is 1 if the specific patient achieved the pathological complete remission (pCR) after the six neoadjuvant chemotherapy (NAC) treatments. Otherwise pCR is 0 if the patient didn't achieve the pathological complete remission after all the six NAC treatments.
Six representative classifiers were evaluated for their prediction performances using sensitivity (Sn), specificity (Sp), Accuracy (Acc), balanced accuracy Avc = (Sn + Sp)/2, and Matthew's correlation coefficient (MCC) [41] - [45] . Sn and Sp were defined as the ratios of correctly predicted positive and negative samples, respectively. Acc was the ratio of correctly predicted samples. MCC was calculated between the samples' predicted pCR values and their real pCR values, and was between −1 and +1. The higher MCC, the better a prediction was.
The six representative classifiers were Support Vector Machine (SVM), k nearest neighbors (KNN), Naïve Bayes (NBayes), Decision Tree (DTree), Random Forest (RF) and extreme gradient boosting (XGB).
The detailed description of the problem setting and prediction algorithms may be found in the Supplementary Materials at http://www.healthinformaticslab.org/supp/.
III. RESULTS
A. SUBTYPE TN: pCR PREDICTION BASED ON THE FIRST THREE TREATMENTS
This study firstly investigated whether a patient's pathological complete remission (pCR) may be predicted by taking only the first three neoadjuvant chemotherapeutic treatments. Each treatment was described by the total area of all the lesion nodes. Six different representative classifiers were utilized to calculate the stratified 5-fold cross validation performances [46] - [51] of the binary classification problem between the subtype TN breast cancer patients with and without pCR, i.e., pCR = 1 and 0, respectively. Three prediction performance metrics were used to compare the six classifiers on the given dataset, i.e., balanced accuracy Avc = (Sn + Sp)/2 [44] , [45] , [52] , sensitivity (Sn) and specificity (Sp), as shown in Figure 1 (a). XGB achieved the best classification Avc = 0.7990 for predicting pCR of the TN breast cancer patients. This suggested that the proposed model may accurately predict whether an TN breast cancer patient would achieve the pathological complete remission (pCR = 1). The next two best classification algorithms are DTree and RF, and both of these two algorithms achieved a slightly worse Avc, about 2% decrease. The second best classifier DTree achieved a slightly worse Sn = 0.7300 than that (Sn = 0.7933) of XGB, but a better Sp = 0.8631 than that (Sp = 0.8048) of XGB. The metrics Sn described how accurately those patients with pCR = 1 may be detected, while Sp described the detection accuracy of the patients with poor prognosis (pCR = 0).
Firstly, the exploratory experimental data suggested that the subtype-TN breast cancer patients may be split into the groups of good (pCR = 1) or poor (pCR = 0) prognosis with reasonable prediction performances, in the measurements of Avc, Sn and Sp. Secondly, the clinicians may choose a classification model based on whether they were more interested in Sn or Sp.
So this study conducted a comprehensive evaluation of the binary classification model for the other three breast cancer subtypes.
B. THE OTHER THREE SUBTYPES: pCR PREDICTION BASED ON THE FIRST THREE TREATMENTS
The pCR of the subtype HER2-positive patients can also be satisfyingly predicted using the data of the first three treatments, as shown in Figure 1 (b). The algorithm KNN achieved the best prediction Avc = 0.7493 and MCC = 0.4725. KNN also outperformed all the other five classifiers in the prediction metrics Sn and Sp. This suggested that after the first three chemotherapeutic treatments, a HER2-positive subtype patient may get an estimation of whether she can achieve the pathological complete remission (pCR = 1) by taking three or more treatments. The data in Figure 1 (b) also demonstrated that the other classification algorithms performed much worse than KNN, with at least a decrease 0.0765 in Avc. Figure 1 (c) and (d) showed that the other two subtypes LBP and LBN had worse pCR prediction performances, which may be due to the limited number of positive samples. The algorithm KNN achieved the best pCR prediction Avc VOLUME 7, 2019 0.5989 and 0.6930 for the two subtypes LBP and LBN, respectively. Although KNN outperformed all the other five classifiers in both Sn and Sp, its prediction sensitivities (Sn) were smaller than 0.5000, and required a reasonable improvement. So this study investigated how our pCR prediction models may be improved in the following sections.
C. ESTIMATING THE LESION AREAS AFTER THE FIRST THREE TREATMENTS
We hypothesized that a pCR prediction model may perform better using data of more treatments. Most patients in our cohort received 6 chemotherapeutic treatments. But chemotherapeutic treatment may induce various adverse drug reactions (ADRs) [31] - [34] . So we chose to estimate the nodal sizes of the next three treatments using the data of the first three ones.
A simple regression function y = ax b + c was chosen to predict nodal sizes of the treatments 4/5/6 using the data of the treatments 1/2/3. The three parameters a, b and c were determined by the training data of the first three treatments. The nodal sizes of some patients reached 0 before treatment 6, which caused program errors for the regression training. So a pseudo-one was added to all the nodal sizes during the training step and was subtracted in the final prediction results. A prediction of the nodal size was defined as a correct prediction if the predicted size has a difference to the real size smaller than 20%.
The regression model was trained on the data of three consecutive treatments and predicted the next treatment. The real data of only the first three treatments were used. So treatment 4 was predicted by the model trained on the real data of treatments 1/2/3. Treatment 5 was predicted by the model trained on the real data of treatments 2/3 and the predicted data of treatment 4. Treatment 6 was predicted by the model trained on the real data of treatment 3 and the predicted data of treatments 4/5.
D. OPTIMIZING THE NODAL SIZE PREDICTION MODELS
All the six binary classification algorithms were evaluated using the real data of treatments 1/2/3 and the regressed data of treatments 4/5/6, as shown in Figure 2 . The classification algorithm XGB still achieved better than the other four classifiers (except for RF) on the subtype TN (Figure 2 (a) ), and its Avc reached 0.7619. But XGB achieved Avc = 0.7990 for the subtype TN using only the real data of the first three treatments, as shown in Figure 2 (a). The best Avc = 0.7748 was achieved by the classifier RF, which also achieved the best Sn = 0.7933. But RF's specificity (Sp) was worse than the three classifiers SVM, XGB and DTree.
The classifiers RF and XGB achieved the best prediction performances in all the three metrics Avc/Sn/Sp for the subtypes HER2 and LBP, as shown in Figure 2 (b) and (c). The prediction performance measurement mAvc was decreased by 0.1026 and 0.0673 by adding the predicted data of treatments 4/5/6 to the training data. The classifier XGB achieved the best Avc = 0.6257 but its specificity (Sp = 0.9181) was slightly worse than that (Sp = 0.9188) of the classifier KNN, as shown in Figure 2 (d) .
The overall pCR prediction of the subtype LBP was significantly improved by integrating the predicted data of treatments 4/5/6 in the training data, as shown in Figure 2 (c). The best pCR prediction model by the data of the first three treatments was achieved by the algorithm KNN, with mAvc = 0.5989. After the data integration of all the six treatments, the algorithm XGB achieved the best performance mAvc = 0.7183, with an increase of 0.1194.
E. SELECTING BEST FEATURES FOR DIFFERENT SUB-TYPES
We further hypothesized that we may need to select different feature combinations for the best pCR prediction performances for the four subtypes [53] - [55] . So we collect the real nodal sizes of the first three treatments (S1, S2, S3) and the predicted nodal sizes of the next three treatments (S4, S5, S6) as the features for each participating patient. A combination of features with the best pCR prediction performance Avc was screened for each classification algorithm on a breast cancer subtype. There were 2 6 = 64 different feature combinations in total for the six features and an exhaustive feature screening step was carried out to find the best feature subset [56] .
The pCR prediction performance Avc reached the best value 0.8696 by the algorithm RF for the subtype TN patients, as shown in Figure 3 (a). Our aforementioned hypothesis was also supported by the observation that this best RF model used only the two features S3 and S4. This model achieved an improvement of 0.0706 for the best Avc = 0.7990 by the algorithm XGB using the three features S1, S2 and S3. Even the same algorithm XGB performed better on these two features S3 and S4, with an improvement 0.0498 in Avc. Both Sn and Sp were also improved compared with the cases in Figures 1 (a) and 2 (a) .
An improved Avc was also obtained for the subtype HER2 patients, as shown in Figure 3 (b) . The algorithm KNN achieved the best Avc = 0.7493 using the first three features S1, S2 and S3 in the above sections. After the step of feature selection, the algorithm XGB achieved a better Avc = 0.7763 using only two features S1 and S6. Another algorithm DTree also achieved a better Avc = 0.7543 using the features S2, S4 and S6. The first three features seem to be the optimal feature subset for the classifier KNN, since it achieved the same performance after the step of feature selection. The two classifiers DTree and KNN outperformed XGB in Sp but not in Sn, as shown in Figure 3 (b) .
The step of feature selection significantly improved the pCR prediction performance for the subtype LBP, as shown in Figure 3 (c). The algorithm KNN achieved the best Avc = 0.5989 using the three original features S1, S2 and S3. After integrating the three predicted features S4, S5 and S6, XGB improved Avc to 0.7183 using all the six features. Figure 3 (c) demonstrated that not every feature positively contributed to the prediction model, and a significant improvement 0.0941 may be achieved by the classifier XGB using only the three features S1, S4 and S6. This best model also improved both Sn and Sp of all the previous models for the subtype LBP.
An increase 0.0399 was achieved for the subtype LBN by the algorithm XGB for Avc by using the two features S3 and S6, as shown in Figure 3 (d) . Even the previous best algorithm KNN was improved with 0.0166 in Avc by using fewer features. And the best model for the subtype LBN was achieved by the classifier RF with Avc = 0.7594 using the features S5 and S6. This best model performed slightly worse in Sp = 0.9188 than that (Sp = 0.9192) of the classifier KNN using the first three features (S1/S2/S3), but it significantly improved the sensitivity (Sn = 0.6000) of the previous best model (Sn = 0.4667).
IV. DISCUSSION
This study explored the possibility of predicting the pathological complete remission (pCR) for breast cancer patients using only the data of the first three chemotherapeutic treatments. At least Avc = 0.7594 (Sn = 0.6000 and Sp = 0.9188) was achieved for the four subtypes of the breast cancer patients, and the algorithm RF may predict pCR for the triple-negative breast cancer (TN) patients with Avc = 0.8696 (Sn = 0.8429 and Sp = 0.8964). It's interesting to observe that the classifier XGB achieved the best accuracies for the two breast cancer subtypes, i.e., HER2 and LBP. And XGB performed the third (Sn = 0.8762 and Sp = 0.8233) and second (Sn = 0.5333 and Sp = 0.9323) best Avc for the other two subtypes TN and LBN, respectively.
The best models utilized the area data (S3, S4), (S1, S6), (S1, S4, S6), (S5, S6) for the subtypes TN, HER2, LBP and LBN, respectively. So the tumor sizes after treatments 1, 3, 4 and 6 were important to predict the final pCR rates, even when S4/S5/S6 were calculated by the regression models of S1/S2/S3.
Our experimental data also demonstrated the importance of selecting a good feature subset for the prediction models. The pCR prediction Avc of the best model was improved from 0.7990 (Sn = 0.7933 and Sp = 0.8048) to 0.8696 (Sn = 0.8429 and Sp = 0.8964) for the subtype TN, with an improvement 0.0706 in Avc. Only two features S3/S4 as the model inputs also reduced the model calculation time. The pCR prediction Avc for the two subtypes LBP and LBN were improved by 0.0941 and 0.0664. The least improvement 0.0270 in Avc was achieved for the subtype HER2.
The subtype-specific pCR prediction models for breast cancers proposed in this study had the potential for clinical applications. Our models focused on simplifying the required input features and calculated the pCR prediction using only the tumor sizes of the first three neoadjuvant chemotherapies. A patient does not have to take a complete series of 6-8 neoadjuvant chemotherapy treatments to determine the prognosis (pCR = 1 or 0). After the first three treatments, the patient may make his or her own decision based on whether this patient was predicted to be able to achieve the pathological complete remission (pCR = 1) or not (pCR = 0) after three additional NAC treatments.
A multi-center clinical trial is being planned to carry out the cross-center validation of our models, before their applications in the clinical practice. Due to the clinical regulations, our models had to take all the procedures to officially get involved in the clinical decision process. We released our models and an easy-to-use pipeline for scientific research purpose only at http://www.healthinformaticslab.org/supp/.
Due to the difficulty in collecting clinical data under a study design, most of the clinical investigations recruited fewer than 300 participants [57] - [63] . This study established the initial pCR prediction models by recruiting 351 breast cancer patients who received at least 6 neoadjuvant chemotherapy treatments. The above-mentioned plan of a multi-center clinical trial will collect more categories of data entries and recruit more breast cancer patients to cross validate our models. This is anticipated to at least partially avoid the overfitting problem of our models and to cover a population in more habitats.
In conclusion, the pathological complete remission (pCR) rate of breast cancer patients undergoing neoadjuvant chemotherapy treatments may be predicted based on the tumor sizes after only the first three treatments. The pCR prediction models may be further improved by describing the heterogeneous status of breast cancer patients from the molecular and imaging perspectives. CHENGYANG YIN is currently pursuing the master's degree in breast surgery with The First Hospital of Jilin University. His research interests include early diagnosis and standardized treatment of breast cancer.
BING HAN is a Chief Physician, a Professor, a Doctor of medicine, and the master's degree Tutor specializes in mammotomy of breast benign tumors, breast cancer surgery, neoadjuvant therapy, standardization, and personalized treatment.
YE DU received the Ph.D. degree in surgery. She is the Deputy Chief Physician, the master's degree Instructor specializes in early diagnosis of breast cancer, surgery, and postoperative individualized comprehensive treatment, benign breast tumor minimally invasive surgery, and intravenous infusion port implantation. 
